What Does Epithelioid Renal AML Mean? Can It Spread?

Seeing the words “epithelioid angiomyolipoma” (epithelioid AML) on your pathology report can be frightening. To answer your question directly: yes, an epithelioid AML can spread (metastasize), but the label “epithelioid” alone does not mean your tumor will inevitably act like cancer ^[1].

Unlike classic AMLs, which are considered benign, epithelioid AMLs have recognized malignant potential. They exist on a spectrum: some may grow slowly and never spread, while others can be aggressive and spread to organs like the liver or lungs ^[2]. Because the exact risk cannot be inferred from the name alone, and because even apparently low-risk tumors do not have a zero percent risk of spreading, each case requires careful, individualized review.

Understanding Your Pathology Report

Classic AMLs are mostly made up of fat, blood vessels, and smooth muscle. An epithelioid AML is characterized by a high number of “epithelioid” cells—cells that look rounder under a microscope, somewhat resembling the epithelial cells that naturally line your organs ^[1].

To help estimate the risk of the tumor spreading, pathologists look for specific “adverse features” (warning signs) in the tissue ^[2]. These features are not a perfect calculator, but an integrated assessment of these signs helps your care team understand the tumor’s potential behavior ^[3]. Important features include:

• Necrosis: Areas of dead tumor cells ^[4].
• High mitotic activity and atypical mitoses: A high number of cells actively dividing, or dividing abnormally ^[2].
• Vascular invasion: Tumor cells growing into nearby blood vessels, particularly the renal vein ^[2].
• Extrarenal extension: The tumor growing past the kidney into surrounding tissues ^[5].
• Marked atypia: Cells that look highly abnormal ^[5].
• Tumor size and margins: Larger tumors often warrant closer follow-up, though size alone is not a strict rule ^[6]. Positive surgical margins (tumor cells at the edge of the removed tissue) also increase risk.

Note: If your diagnosis is based on a core needle biopsy, the needle may not have sampled the whole tumor. Therefore, a biopsy cannot reliably exclude features like necrosis or extrarenal extension.

Getting the Diagnosis Right

Epithelioid AMLs can look virtually identical to certain types of kidney cancer, especially renal cell carcinoma (RCC) ^[7]. Diagnosis relies on the tumor’s visual appearance combined with a panel of specialized stains (immunohistochemistry) to find specific proteins.

• Markers supporting EAML: Epithelioid AMLs often test positive for melanocytic markers (like HMB-45 and Melan-A) and smooth-muscle markers (like SMA) ^[8].
• Markers supporting RCC: Epithelioid AML is usually negative for PAX8 (a marker commonly expressed in RCC) and cytokeratins ^[9].

However, staining can be variable or patchy, and no single stain completely rules a diagnosis in or out ^[10].

In some cases, genetic testing on the tumor tissue is performed. Mutations in the TSC1 or TSC2 genes are common in these tumors ^[11]. It is important to know the difference between a somatic mutation (acquired only in the tumor) and a germline mutation (inherited, causing Tuberous Sclerosis Complex, or TSC) ^[12]. Finding a mutation in the tumor does not automatically mean you inherited TSC. However, if you are young, have tumors in both kidneys, or have a family history of TSC, your doctor may recommend genetic counseling and a blood test for inherited TSC ^[13]. Rarely, testing for TFE3 fusions is needed if the tumor closely mimics a specific rare cancer called TFE3-rearranged RCC ^[14].

Next Steps for Your Care

Because this tumor is rare and has malignant potential, management should be highly individualized.

• Expert Pathology Review: Have your slides reviewed by a pathologist experienced with rare genitourinary (GU) tumors ^[6]. This can often be done by sending the slides to a major center without you needing to travel.
• Staging and Imaging: To determine if the tumor has spread, your team may recommend baseline cross-sectional imaging (CT or MRI) of your chest, abdomen, and pelvis ^[15]. This staging helps determine the best surgical or treatment approach.
• Surgery: For a localized tumor, complete surgical removal is the primary treatment ^[16]. You and your urologist will discuss whether a partial nephrectomy (removing just the tumor) or radical nephrectomy (removing the whole kidney) is most appropriate, balancing the need to remove the tumor completely against protecting your kidney function.
• Long-Term Follow-Up: Because epithelioid AML can recur or spread even years later, long-term follow-up imaging is important ^[2]. There is no single, universally accepted imaging schedule; your plan will be customized based on your tumor’s features, stage, and margins ^[17]. Many patients experience no symptoms if the tumor returns, which is why attending scheduled scans is vital.
• Systemic Therapy: If the tumor cannot be removed safely or has spread, your case should be reviewed by a multidisciplinary tumor board (including a urologist, medical oncologist, and pathologist). While evidence is currently limited to small case series and reports, specialist-directed systemic therapy with an mTOR inhibitor (such as everolimus) is sometimes considered for selected advanced cases ^[18].

🚨 When to Seek Urgent Medical Care

Do not wait for a scheduled follow-up scan if you experience:

• Sudden, severe flank, back, or abdominal pain
• Visible blood in your urine (gross hematuria)
• Fainting, dizziness, or marked weakness

These can be signs of sudden internal bleeding or other acute kidney problems and require urgent medical evaluation. General symptoms like unexplained weight loss, new breathing difficulties, or persistent fatigue should also be reported promptly to your care team.